BioCentury
ARTICLE | Product Development

Intermediate decision-making

January 5, 2009 8:00 AM UTC

Oncotype DX from Genomic Health Inc. is used in over 50% of breast cancer patients to determine if they are at risk of recurrence and thus should receive chemotherapy following surgery. The problem is what to do with patients who receive an intermediate score.

bioMerieux S.A.'s bioTheranostics Inc. subsidiary thinks it has a potential solution. The company has data showing its Theros BCI genomic test for breast cancer recurrence risk was able to re-stratify these patients into high and low risk groups, which could help oncologists make better treatment decisions...